Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:tobacco
gptkb:depression |
| gptkbp:approves |
gptkb:1985
seasonal affective disorder smoking cessation major depressive disorder |
| gptkbp:available_on |
gptkb:tablet
extended-release tablet sustained-release tablet |
| gptkbp:brand |
gptkb:Zyban
gptkb:Wellbutrin gptkb:Aplenzin Forfivo XL |
| gptkbp:casnumber |
31677-93-7
|
| gptkbp:category |
gptkb:C
|
| gptkbp:chemical_formula |
C13 H18 Cl NO2
|
| gptkbp:class |
aminoketone
atypical antidepressant |
| gptkbp:clinical_use |
gptkb:post-traumatic_stress_disorder
chronic pain anxiety disorders bipolar disorder attention deficit hyperactivity disorder social anxiety disorder generalized anxiety disorder obsessive-compulsive disorder panic disorder depression in adults |
| gptkbp:contraindication |
eating disorders
alcohol withdrawal seizure disorder |
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
150 mg daily
400 mg daily 300 mg daily |
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
oral
|
| https://www.w3.org/2000/01/rdf-schema#label |
bupropion
|
| gptkbp:interacts_with |
antihistamines
antipsychotics opioids monoamine oxidase inhibitors other antidepressants |
| gptkbp:lifespan |
21 hours
|
| gptkbp:mechanism_of_action |
norepinephrine-dopamine reuptake inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:side_effect |
anxiety
dizziness nausea insomnia dry mouth |
| gptkbp:bfsParent |
gptkb:CYP2_D6
|
| gptkbp:bfsLayer |
4
|